Roche enters the SERD market with FDA approval in late-stage breast cancer
Roche’s big-hope breast cancer pill giredestrant was in an odd situation in that it was awaiting two different FDA approval decisions. Also oddly, the second …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







